THERAPEUTIC DRUG-MONITORING OF ANTICONVULSANTS - STATE-OF-THE-ART

被引:48
作者
CHOONARA, IA [1 ]
RANE, A [1 ]
机构
[1] UNIV HOSP UPPSALA, DIV CLIN PHARMACOL, UPPSALA, SWEDEN
关键词
D O I
10.2165/00003088-199018040-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is considerable interindividual variation in the relationship between control of seizures and the serum anticonvulsant concentration. The minimum effective serum concentration is dependent on the type and severity of the epilepsy, and varies from patient to patient. The therapeutic range should be used as a guide to adjust the dose in order to further improve seizure control or reduce toxicity; the latter is more likely with higher serum concentrations, but can also be present when concentrations are low. A request for the serum concentration of an anticonvulsant should be made only for good clinical reasons, and an interpretation of that concentration can only be made if all the relevant clinical details are available. Indications for the measurement of serum anticonvulsant concentrations include poor seizure control, toxicity, suspected gross noncompliance, status epilepticus and the elapse of 2 to 4 weeks after the initiation of therapy. Additional drug therapy, pregnancy or illness may alter drug disposition in a well controlled patient and therapeutic drug monitoring may, therefore, help to prevent seizures secondary to these changes. The measurement of anticonvulsants in saliva as opposed to serum may be of benefit in some patients. © 1990, ADIS Press Limited. All rights reserved.
引用
收藏
页码:318 / 328
页数:11
相关论文
共 101 条
[11]   ETHOSUXIMIDE IN TREATMENT OF ABSENCE (PETIT MAL) SEIZURES [J].
BROWNE, TR ;
DREIFUSS, FE ;
DYKEN, PR ;
GOODE, DJ ;
PENRY, JK ;
PORTER, RJ ;
WHITE, BG ;
WHITE, PT .
NEUROLOGY, 1975, 25 (06) :515-524
[12]   DIPHENYLHYDANTOIN (DILANTIN) AND PHENOBARBITAL BLOOD LEVELS IN EPILEPTIC CHILDREN [J].
BUCHANAN, RA ;
ALLEN, RJ .
NEUROLOGY, 1971, 21 (08) :866-&
[13]   CLINICAL AND ELECTROENCEPHALOGRAPHIC CORRELATIONS WITH SERUM LEVELS OF DIPHENYLHYDANTOIN [J].
BUCHTHAL, F ;
SVENSMARK, O ;
SCHILLER, PJ .
ARCHIVES OF NEUROLOGY, 1960, 2 (JUN) :624-630
[14]  
BUCHTHAL F, 1971, PSYCHIAT NEUROL NEUR, V74, P117
[15]   A PROSPECTIVE-STUDY BETWEEN CARBAMAZEPINE, PHENYTOIN AND SODIUM VALPROATE AS MONOTHERAPY IN PREVIOUSLY UNTREATED AND RECENTLY DIAGNOSED PATIENTS WITH EPILEPSY [J].
CALLAGHAN, N ;
KENNY, RA ;
ONEILL, B ;
CROWLEY, M ;
GOGGIN, T .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1985, 48 (07) :639-644
[16]   CARBAMAZEPINE AS A SINGLE DRUG IN TREATMENT OF EPILEPSY - PROSPECTIVE-STUDY OF SERUM LEVELS AND SEIZURE CONTROL [J].
CALLAGHAN, N ;
OCALLAGHAN, M ;
DUGGAN, B ;
FEELY, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1978, 41 (10) :907-912
[17]   CARBAMAZEPINE FOR EPILEPSY - CONTROLLED PROSPECTIVE EVALUATION [J].
CEREGHINO, JJ ;
BROCK, JT ;
VANMETER, JC ;
PENRY, JK ;
SMITH, LD ;
WHITE, BG .
NEUROLOGY, 1974, 24 (05) :401-410
[18]   SERUM ANTICONVULSANT CONCENTRATIONS AND THE RISK OF DRUG-INDUCED SKIN ERUPTIONS [J].
CHADWICK, D ;
SHAW, MDM ;
FOY, P ;
RAWLINS, MD ;
TURNBULL, DM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1984, 47 (06) :642-644
[19]  
CHEN SS, 1982, BRIT J CLIN PHARMACO, V13, P547
[20]  
CHOONARA IA, 1988, BRIT J CLIN PHARMACO, V26, pP233